Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 10;12(10):e0185198. doi: 10.1371/journal.pone.0185198

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Thein et al

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Fig 2 — A-F. Estimates of incremental net benefit (i.e. incremental cost-effectiveness ratio, ICER) and its 95% confidence intervals as a function of willingness-to-pay threshold for an additional life year: (A) transarterial chemoembolization (TACE) alone or TACE+sorafenib vs. no treatment or best supportive care (BSC); (B) non-sorafenib chemotherapy alone vs. BSC; and (C) sorafenib alone vs. BSC; and for an additional quality-adjusted life year (QALY): (D) TACE alone or TACE+sorafenib vs. BSC; (E) non-sorafenib chemotherapy alone vs. BSC; and (F) sorafenib alone vs. BSC.